Form 4: Entrada Therapeutics Director Kush Parmar Acquires 16,000 Stock Options

Director Kush Parmar acquired 16,000 stock options in Entrada Therapeutics, Inc. on June 13, 2024.

Summary

• On June 13, 2024, Kush Parmar, a director of Entrada Therapeutics, Inc., acquired 16,000 stock options.
• The exercise price of these options is $16.45.
• The options vest on the earlier of June 13, 2025, or the Issuer's next annual meeting of stockholders.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction. The director's acquisition of options could be seen as a slightly positive signal, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule and expiration date of the options provide a timeline for potential future exercises.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives and directors as part of their overall compensation packages.
• The vesting schedules and exercise prices are typically structured to align the interests of the executives with those of the shareholders.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates